Vascular endothelial growth factors promote neovascularization and break the blood-retinal barrier. Anti-vascular endothelial growth factor (anti-VEGF) therapies block VEGF's actions, decreasing abnormal new blood vessel formation and retinal leakage/swelling. This stabilizes vision and may improve it. Bevacizumab, ranibizumab, and aflibercept are examples of anti-VEGF drugs used intravitreally to treat wet age-related macular degeneration, diabetic retinopathy, retinal vein occlusion and other conditions. While effective, anti-VEGF therapies require frequent injections and monitoring for side effects like increased intraocular pressure.
Fungal infections of eye cause one of the most dangerious infections. Accurate diagnosis and proper institution of anti-fungal therapy is essential. Here we discuss the various anti-fungal agents available to be used in ophthalmology.
Fungal infections of eye cause one of the most dangerious infections. Accurate diagnosis and proper institution of anti-fungal therapy is essential. Here we discuss the various anti-fungal agents available to be used in ophthalmology.
Pseudophakic bullous keratopathy (PBK) is a post-operative condition that can occur as a complication of cataract extraction surgery and intraocular lens placement.
May be manifest in the immediate post-operative period or symptoms may not present for many years.
Diabetic maculopathy is a form of damage to the eye causing by diabetic macular oedema where fluids build up on the macula. It can be cured by laser surgeries.
This is a slideshow presentation about common antimetabolites usage in ophthalmology. It included the summary of mode of actions, indication, contraindication, preparation, pharmacokinetic and pharmacodynamic of each drugs.
Pseudophakic bullous keratopathy (PBK) is a post-operative condition that can occur as a complication of cataract extraction surgery and intraocular lens placement.
May be manifest in the immediate post-operative period or symptoms may not present for many years.
Diabetic maculopathy is a form of damage to the eye causing by diabetic macular oedema where fluids build up on the macula. It can be cured by laser surgeries.
This is a slideshow presentation about common antimetabolites usage in ophthalmology. It included the summary of mode of actions, indication, contraindication, preparation, pharmacokinetic and pharmacodynamic of each drugs.
medical management of chronic open angle glaucoma, primary angle closure glaucoma after iridotomy, normotensive glaucoma and acute angle closure attack.
Normal Labour/ Stages of Labour/ Mechanism of LabourWasim Ak
Normal labor is also termed spontaneous labor, defined as the natural physiological process through which the fetus, placenta, and membranes are expelled from the uterus through the birth canal at term (37 to 42 weeks
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...NelTorrente
In this research, it concludes that while the readiness of teachers in Caloocan City to implement the MATATAG Curriculum is generally positive, targeted efforts in professional development, resource distribution, support networks, and comprehensive preparation can address the existing gaps and ensure successful curriculum implementation.
A workshop hosted by the South African Journal of Science aimed at postgraduate students and early career researchers with little or no experience in writing and publishing journal articles.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
How to Build a Module in Odoo 17 Using the Scaffold MethodCeline George
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
How to Build a Module in Odoo 17 Using the Scaffold Method
Anti vegf
1.
2. Vasculo endothelial growth factors are
molecules produced by endothelial
cells,pericytes,RPE,muller cells and glial
cells to promote neovascularisation
Also responsible for break in blood retinal
barrier
The future implications and indications of anti-vascular endothelial growth factor
therapy in ophthalmic practice IJO
4. The antibodies which blocks the actions of VEGFs are
anti VEGFs
thus benefit the patients by decreasing the abnormal
and harmful new blood vessels formation and by
decreasing the leakage and swelling of the retina.
This leads to stabilization of vision and even
improvement in vision in many cases.
The future implications and indications of anti-vascular endothelial growth factor therapy in
ophthalmic practice IJO
5. ANTI VEGF
PEGABTANIB RANIBIZUMAB BEVACIZUMAB
MACUGEN LUCENTIS AVASTIN
The future implications and indications of anti-vascular endothelial growth factor
therapy in ophthalmic practice IJO
6. Humanized monoclonal antibody
Active against all isoforms of VEGFs
Received its first approval in 2004
Rosenfield et al were the first ones to describe &
publish the off label use of intravitreal
Bevacizumab in 2005.
MECHANISM OF ACTION: Bevacizumab (Avastin)
binds directly to VEGF Forms protein complex
Incapable of further binding to VEGF receptor
sites which would initiate vessel growth
effectively reducing available VEGF
The future implications and indications of anti-vascular endothelial growth factor therapy in
ophthalmic practice IJO
7. Off-label use as an intravitreal agent in the
treatment of proliferative (neovascular) eye
diseases Particularly for Choroidal neovascular
membrane (CNV) in AMD. (not currently
approved by the FDA for such use)
The injection of 1.25-2.5 mg of –NO significant
intraocular toxicity.
Noted impressive results in the setting of: 1. CNV
2. Proliferative diabetic retinopathy 3.
Neovascular glaucoma 4. Diabetic macular
edema 5. Retinopathy of prematurity 6. Macular
edema secondary to retinal vein occlusions.
8. Typically given by transconjunctival intravitreal
injections.
Intravitreal injections for retinal pathologies are
typically administered at 4-6 week intervals,
although this varies widely based on disease and
response.
DOSE: Typical dose is 1.25mg in 0.05ml in adults,
and half that dose in babies.
COMBINATION THERAPY: Photodynamic
Therapy Anti PDGF Intravitreal Triamcinolone
Triple Therapy Radiation
BENEFITS: Reduces frequency of injections
Reduces recurrence
10. RANIBIZUMAB
NON BINDING FRAGMENT Fab FRAGMENT
MAKES IT HUMANISED MOUSE DERIVED
LESS ANTIGENIC ACTIVE AGAINST ALL VEGF
ISOFORMS
HIGH AFFINITY BINDING SITE
The future implications and indications of anti-vascular endothelial growth factor
therapy in ophthalmic practice IJO
11. Lucentis is an monoclonal antibody fragment
(Fab) developed from the identical parent
antibody as Avastin.
Lucentis was approved for neovascular AMD
in the U.S. in 2006
MECHANISM OF ACTION: Much smaller than
the parent molecule and has been affinity
stronger binding to VEGF-A.
Anti-angiogenic property. Unlike the full
length antibody, it penetrates the ILM and
can gain access to the sub retinal space.
12. Available as Injection, intravitreal 10 mg/mL
Dose: 0.5 mg/0.05 ml once every month
PHARMACOKINETICS: Vitreous t1/2 = 3 days
(animals) 9 days (humans) Serum concentrations
upto 2000x lower than in the vitreous.
Reduction in Ranibizumab clearance in renal
impairment is considered clinically insignificant &
dose adjustment is not expected to be needed.
DRUG INTERACTIONS: Have not been studied.
SAFETY PROFILE: Serious ocular adverse events in 2
year MARINA study for ranibizumab 0.5 mg:
1. Endophthalmitis – 1.3% 2. Uveitis – 1.3% . 3. Retinal
tear – 0.4% 4. Lens damage – 0.4%
Serious ocular adverse events in 1 year ANCHOR study for ranibizumab 0.5 mg : 1.
Endophthalmitis – 1.4 % 2. Uveitis – 0.7% There was no increase in systemic adverse effects such
as HTN, arterial thromboembolism in either study.
13. PEGABTANIN
FIRST ANTI ANGIOGENIC AGENT
28 BASE RNA APTAMER SELECTIVELY BIND VEGF 165
NON IMMUNOGENIC DOEST NOT AFFECT NORMAL
VASCULAR GROWTH
14. Pegylated Aptamer Pegaptanib sodium
injection (brand name Macugen) is an anti-
angiogenic medicine for the treatment of
neovascular WET AMD.
Discovered by Gilead Sciences and licensed in
2000 to EyeTech Pharmaceuticals.
Approval was granted U.S.(FDA) in Dec 2004.
MECHANISM OF ACTION: Specifically binds to
VEGF 165 ISOMER Protein that plays a critical
role in angiogenesis (the formation of new blood
vessels) Increased permeability (leakage from
blood vessels) Two primary pathological processes
responsible for vision loss associated with neovascular
AMD.
15. ADMINISTRATION AND DOSAGE:
Administered in a 0.3 mg dose once every six
weeks by intravitreal injection.
Marketed as a pre-filled syringe.
CONTRAINDICATED ocular or periocular
infections.
PHARMACOKINETICS: (Not adequately studied in
humans) Absorption Very slow systemic
absorption Occurs within 1 to 4 days after 0.3
mg monocular dose. Metabolism & Excretion By
Endo & Exonucleases excreted by kidney.
DRUG INTERACTIONS: Not affected by
Cytochrome P450 system.
16. BEVACIZUMAB RANIBIZUMAB
FULL SIZED ANTIBODY ANTIBODY FRAGMENT
148 KILODALTONS 48 KILODALTONS
HALF LIFE 20 DAYS HALF LIFE 3 DAYS
SLOW CLEARANCE 100 TIMES FASTER
COSTs LESS COSTLY
Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal
neovascular membrane in age-related macular degeneration IJO
17. Recombinant fusion protein consisting of VEGF- binding
portions from the extracellular domains of human VEGF
receptors 1 and 2, that are fused to the Fc portion of the
human IgG1 immunoglobulin.
INDICATIONS :1. Neovascular (Wet) ARMD Recommended
dose for EYLEA is 2 mg (0.05 mL or 50 microliters).
Administered by intravitreal injection every 4 weeks
(monthly) for the first 12 weeks (3 months), followed by 2
mg (0.05 mL) via intravitreal injection once every 8 weeks
(2 months).
Macular Edema Following CRVO Recommended dose for
EYLEA is 2 mg (0.05 mL or 50 microliters). Administered
by intravitreal injection once every 4 weeks.
CONTRAINDICATIONS: infections or active inflammations
of or near the eye
AFLIBERCEPT is moving through clinical trials for further
intraocular and systemic indications.
18. TOPICAL ANAESTHESIA GIVEN
PAINTING WITH BETADINE WITH INSTILLATION OF
BETADINE IN CONJUNCTIVAL SAC
DRUG TAKEN IN TUBERCULIN SYRINGE WITH 30G
NEEDLE (1.25MG/0.05ML)
ASK PATIENT TO LOOK DOWN
FROM SUPEROTEMPORAL QUADRANT 4mm AWAY
FROM LIMBUS NEEDLE IS INSERTED TOWARDS
CENTRE OF GLOBE AND DRUG INJECTED
INJECTION SITE PRESSED WITH COTTON BUD
Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal
neovascular membrane in age-related macular degeneration IJO
19. Injection volume : An injection volume of
0.05 mL is most commonly used.
Safe volume to inject without preinjection
paracentesis is believed to be 0.1 mL to 0.2
mL.
Larger injection volumes are uncommon,
exceptions: injection of gas for pneumatic
retinopexy
the injection of multiple intravitreal agents
in one session.
20. Needle selection Needle size varies according to the substance injected, with 27-
gauge needles -triamcinolone acetonide and 30- gauge needles -anti-VEGF agents
ranibizumab, bevacizumab, and aflibercept.
Studies suggest that smaller, sharper needles require less force for penetration and
result in less drug reflux. Needle length between 0.5 and 0.62 inches (12.7 to
15.75 mm) is recommended, as longer needles may increase risk of retinal injury if
the patient accidentally moves forward during the procedure.
Injection site The patient should be instructed to direct his or her gaze away
from the site of needle entry. The injection is placed 3 to 3.5 mm posterior to the
limbus for an aphakic or pseudophakic eye, and 3.5 to 4 mm posterior to the limbus
for a phakic eye. Injection in the inferotemporal quadrant is common.
Injection technique Some guidelines suggest pulling the conjunctiva over the
injection site with forceps or a sterile cotton swab to create a steplike entry path.
While this approach may, in theory, decrease reflux and risk of infection, a straight
injection path is most commonly employed. After the sclera is penetrated, the
needle is advanced toward the center of the globe and the solution is gently
injected into the midvitreous cavity.
The needle is removed, and a sterile cotton swab is immediately placed over the
injection site to prevent reflux. IOP and CRA perfusion is assessed. Topical
Antibiotic is administered for one week.
21.
22. Wet Age-Related Macular Degeneration
Proliferative Diabetic Retinopathy
Retinal Vein Occlusion
CNVM
Neovascular Glaucoma
Macular Edema
Vitreous Hmg
Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal
neovascular membrane in age-related macular degeneration IJO
23. POSTERIOR SEGMENT
ROP
EALES disease
Refractory post surgical
CME.
COATS disease
ANTERIOR SEGMENT
Iris neovascularization
Before Keratoplasty to
reduce to reduce
corneal
neovascularization
(2.25mg IN 0.1ml near corneal
vasc.)
Pterygium
(1.35mg/0.05m s/c)
Trabeculectomy (to
modulate wound
healing
24. Raised IOP (13-17.6%)
Cataract (0.07%)
Endophthal mitis (0.1- 1%)
Risk of ATE(4.6%)( decrease the synthesis of
matrix metalloprote inases)
Rebound macular edema Immunoreac
tivity(4.4- 6.3%)
Retinal detatchment (0.08%)
Central Retinal Artery Occlusion
25. 1.Fibrovascular proliferation threatening the
macula
2. Active ocular or periocular inflammation
3. Known hypersensitivity to drugs
4. Uncontrolled hypertension 5.
Cardiovascular disease
6. Pregnancy and lactation
7. Pre pubescent children
26. For the treatment of patients with wet
AMD, DME, RVO, or CNV due to PM,
bevacizumab is the preferred initial anti-
VEGF therapy, based on similar clinical
effectiveness and lower cost compared
with other anti-VEGF treatments.
27. Ranibizumab or aflibercept can be used as
alternative treatment options in patients
who do not respond to bevacizumab or in
patients who experience
thromboembolism following the initiation
of bevacizumab treatment or who are at a
high risk of cardiovascular adverse events
28. The frequency and dose of intravitreal
injections of the anti-VEGF drugs should be
determined by the treating ophthalmologist
dose should not exceed that recommended
for a particular retinal condition by the
product monograph (if available) or that used
in randomized clinical trials.
Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal
neovascular membrane in age-related macular degeneration IJO
29. Nowadays, anti-VEGF therapy has become
one of the more frequently applied
treatment modalities in ophthalmology.
The indications for its usage have become
wider and wider, but investigators still are
looking for new drugs with more
prolonged time of action or new forms of
drugs delivery.
30. M. Rajappa, P. Saxena, and J. Kaur, “Ocular
angiogenesis: mechanisms and recent advances
in therapy,” Advances in Clinical Chemistry, vol.
50, pp. 103–121, 2010.
PMLive, “Top Pharma list,” November 2014
J. G. Arroyo, “Towards a rational approach to
combination therapy for neovascular age
related macular degeneration,” The British
Journal of Ophthalmology, vol. 91, no. 2, pp.
130–131, 2007.
31. J. W. Miller, A. P. Adamis, D. T. Shima et al.,
“Vascular endothelial growth factor/vascular
permeability factor is temporally and
spatially correlated with ocular angiogenesis
in a primate model,” American Journal of
Pathology, vol. 145, no. 3, pp. 574–584, 1994
L. P. Aiello, R. L. Avery, P. G. Arrigg et al.,
“Vascular endothelial growth factor in ocular
fluid of patients with diabetic retinopathy
and other retinal disorders,” The New
England Journal of Medicine, vol. 331, no.
22, pp. 1480–1487, 1994.
32. M. S. Gordon, K. Margolin, M. Talpaz et al.,
“Phase I safety and pharmacokinetic study of
recombinant human anti-vascular endothelial
growth factor in patients with advanced
cancer,” Journal of Clinical Oncology, vol. 19,
no. 3, pp. 843–850, 2001
E. S. Gragoudas, A. P. Adamis, E. T.
Cunningham Jr., M. Feinsod, and D. R. Guyer,
“Pegaptanib for neovascular age-related
macular degeneration,” The New England
Journal of Medicine, vol. 351, no. 27, pp.
2805–2816, 2004.
33. The era of anti-vascular endothelial growth
factor (VEGF) drugs in ophthalmology, VEGF
and anti-VEGF therapy
Dorota Pożarowska1 and Piotr Pożarowski2
Author information ► Article
notes ► Copyright and License
information ► Disclaimer
, for combination use with standard chemotherapy for metastatic colon cancer It has since been approved for use in ◦ Certain lung cancers, ◦ Renal cancers, ◦ Ovarian cancers ◦ Glioblastoma multiforme of the brain
all stage 3 + ROP. However, results revealed that safety was still an issue. Choroidal rupture has been reported with injection of bevacizumab. Adverse influence on the development of choroidal vessels.
Recent articles have suggested intraocular bevacizumab as a new form of treatment in neovascular eales disease or as a possible adjunctive treatment to vitreoretinal surgery for the management of eales disease with tractional retinal detachment. However, this treatment has a legacy of serious complications like secondary rhegmatogenous retinal detachment, within a week of receiving intravitreal bevacizumab. Combination therapy of laser treatment and intraocular bevacizumab was effective in improving and stabilizing the vision.
VEGF have been detected in pterygium.There is marked elevation of VEGF in pterygia in comparison to normal conjunctival samples. Subconjunctival bevacizumab is used in recurrent pterygium. Topical bevacizumab is used in the treatment of corneal neovascular vessels, higher concentration has adverse effects. Therefore, duration of treatment may well determine the safety of topical bevacizumab